Emerald BioStructures’ Structural Biology Expertise Supports Advancement of Three New Drug Candidates to Clinical Development

BAINBRIDGE ISLAND, Wash.--(BUSINESS WIRE)--Emerald BioStructures, a leading provider of integrated structural biology services, today announced that protein crystal structures determined at Emerald BioStructures have supported the advancement of three drug candidates to clinical trials, for leukemia, asthma, and spinal muscular atrophy. This milestone brings the total count of Emerald’s collaborator INDs (investigational new drugs) to eight, with six of these in clinical trials, and makes Emerald BioStructures one of the most prolific structure-based drug design contract service organizations in the world.